Dextroamphetamine-Class Medications in Pregnancy

IExecutive Summary

Clinical management of ADHD during pregnancy has shifted from a default "discontinue at all costs" approach to a nuanced, functional impairment model. For many women, untreated ADHD in pregnancy is not a benign state — it carries its own risks to maternal safety, occupational stability, and mental health.

Adults with ADHD demonstrate higher risk of traffic accidents and injuries, poorer occupational performance, and higher probability of unemployment.^13,14 ADHD symptoms during pregnancy are associated with elevated stress, depressive symptoms, and reduced perceived social support, all of which independently affect obstetric and neonatal outcomes.^6,17 The 2023 ACOG Clinical Practice Guideline on perinatal mental health (CPG No. 5) addresses depression, anxiety, bipolar disorder, and psychosis but does not include ADHD-specific recommendations.⁶ Its general principle — that treatment decisions must weigh the risks of untreated illness alongside medication exposure — applies by extension to ADHD, but readers should note no major obstetric or psychiatric society has issued ADHD-specific perinatal guidelines as of this writing.

Dextroamphetamine-based medications are now considered a viable option when the benefits of maternal stability outweigh the manageable risks of adverse obstetric outcomes. The recent 2025 systematic review concluded that for women in whom ADHD medication is effective, the benefits of continuation are likely to outweigh the risks, while emphasizing individualized decision-making.¹⁷

IIDextroamphetamine-Class Comparison

This class encompasses several formulations of amphetamine salts. Selection during pregnancy is often guided by the desire for the smoothest maternal plasma concentration profile, minimizing peak exposures that may transiently affect uterine artery resistance.

IIIClinical Risk Profile

1. Teratogenic Profile (First Trimester)

Major Malformations

The largest dataset to date — the International Pregnancy Safety Study Consortium — analyzed 1.8 million pregnancies including 5,571 amphetamine-exposed and 2,072 methylphenidate-exposed first-trimester exposures.¹ After full propensity score adjustment:

First-trimester amphetamine exposure was not associated with any congenital malformation or cardiac malformation. This contrasts with methylphenidate, which in the same study showed a persistent signal for cardiac malformations (RR 1.28; 95% CI 0.94–1.74).¹

The MGH National Pregnancy Registry for Psychiatric Medications (N=1,988) reported an OR of 0.39 (95% CI 0.09–1.61) for major malformations after first-trimester exposure to any stimulant compared with controls. Notably, no major malformations were observed among infants exposed to lisdexamfetamine (n=40) or methylphenidate (n=45).²

2. Obstetric and Placental Risks

Stimulants are sympathomimetic and can affect maternal hemodynamics and uterine blood flow. A critical clinical insight from recent literature is that risk is duration-dependent — first-trimester-only exposure and continued exposure through the second and third trimesters carry meaningfully different risk profiles.

The Highest Signal: Newport 2016

An early, smaller single-center prospective study by Newport et al. (n=686) provides the strongest signal in the literature: psychostimulant exposure after the 20th week of gestation was associated with hypertensive disorders of pregnancy with an adjusted OR of 6.11 (95% CI 1.79–20.9), with a dose-response relationship demonstrated specifically for amphetamine psychostimulants.¹⁸ Important caveats: this analysis was based on only 12 pregnancies exposed after week 20, the confidence interval is correspondingly wide, and the population was drawn from a tertiary academic perinatal psychiatry program (i.e., higher-acuity than a general obstetric cohort). The signal direction is consistent with the larger Medicaid and commercial-claims studies, even if the magnitude is likely inflated by small numbers and selection.

The Confounder Question

Working in the opposite direction: a distributed analysis across Ontario and New South Wales found that the preeclampsia signal attenuated substantially with better confounder control (weighted OR 1.24; 95% CI 0.64–2.40 in the restricted analysis), suggesting that residual confounding by maternal psychiatric severity, substance use, and cardiometabolic comorbidities may partially explain the observed associations.⁷

An Australian cohort study specifically of dexamphetamine users compared continuers with ceasers and an unexposed reference group. Ceasers (those who stopped during pregnancy) had higher odds of threatened abortion (OR 2.28; 95% CI 1.00–5.15) compared to continuers. While the unexposed group had lower rates of preeclampsia than continuers, the continuation-vs-cessation comparison did not show increased adverse outcomes from continuing dexamphetamine.¹⁷

3. Neonatal Adaptation

FDA labeling notes that "neonates exposed to amphetamine in utero are at risk for withdrawal symptoms following delivery."^8,10 In clinical practice, jitteriness, mild irritability, poor feeding, or sleep disturbance may occur in the first 24–72 hours but is typically mild and self-limiting. Severe neonatal abstinence syndrome is uncommon with therapeutic doses.

4. Long-Term Neurodevelopmental Outcomes

The largest neurodevelopmental study to date — a cohort of over 4.27 million insured pregnancies (Medicaid 2000–2018; MarketScan 2003–2020) with up to 14–18 years of follow-up — evaluated children exposed to amphetamine/dextroamphetamine in the second half of pregnancy.⁵

In unadjusted analyses, exposure was associated with a 2- to 3-fold increased risk of neurodevelopmental outcomes. After adjustment for maternal ADHD severity and related confounders, the increased risk disappeared entirely:

The unadjusted signal was entirely explained by confounding — maternal ADHD itself, and the genetic, behavioral, and socioeconomic factors that accompany it, account for the apparent elevated risk in offspring, not the medication.^5,17

The unadjusted 2- to 3-fold increased risk was entirely explained by maternal confounders — not the medication itself.

IVPre-Conception Counseling

The ideal time to discuss stimulant management is before pregnancy. Up to 50% of pregnancies in the U.S. are unplanned, so any reproductive-age woman on stimulant therapy should have this conversation documented at routine follow-up. Key elements:

Components of the Pre-Conception Visit

• Confirm ADHD diagnosis and severity: Review functional impairment, prior trials off medication, and history of medication response. Mild cases may not require continuation in pregnancy.
• Optimize the dose: Patients on supratherapeutic doses should be titrated to the lowest effective dose before conception.
• Switch to a preferred formulation: Transition to lisdexamfetamine or an XR formulation 1–3 months pre-conception to assess tolerability before fetal exposure.
• Screen for comorbid hypertension and cardiometabolic risk: Baseline BP, BMI, and cardiac history; these are the strongest modifiable risk factors for preeclampsia.
• Start folic acid: 400–800 mcg daily (or 4 mg if prior NTD-affected pregnancy). Not stimulant-specific, but pre-conception folate is mandatory.
• Discuss substance use: Confirm no concurrent stimulant misuse, illicit drug use, alcohol, or tobacco — these dwarf the risks of therapeutic stimulants.
• Coordinate with OB/GYN: If high-risk obstetric history (prior preeclampsia, IUGR, preterm delivery), discuss whether MFM consultation pre-conception would be valuable.
• Plan for low-aspirin prophylaxis: ACOG recommends 81 mg aspirin daily from 12 weeks for women at moderate-high risk of preeclampsia. Stimulant use is a relative risk factor that may push borderline patients into the prophylaxis tier.⁶

VClinical Decision Algorithm

A structured approach to the woman of reproductive age on stimulant therapy, or the newly pregnant patient asking what to do.

VIManagement Strategy: The "Safe-Start" Protocol

(1) Formulation Selection

Extended-release (XR) or prodrug (lisdexamfetamine) formulations are generally favored over immediate-release (IR) products to provide steadier maternal plasma concentrations.

• IR strategy: Useful for supplementing an ER dose or for patients who need only 4 hours of focused executive function (e.g., morning work blocks). The rapid peak is theoretically more likely to transiently impact uterine artery resistance, though this has not been directly demonstrated clinically.
• ER strategy: Generally favored to provide steady maternal executive function throughout the day, minimizing the number of times the fetus is exposed to rising drug concentrations.

(2) The Prodrug Advantage — Lisdexamfetamine

Lisdexamfetamine (Vyvanse) is enzymatically converted to d-amphetamine in red blood cells — not the GI tract — producing a smoother pharmacokinetic curve and reducing peak-related side effects. Animal reproduction studies showed no effects on embryo-fetal morphological development or survival when administered during organogenesis.^10,11 The MGH Pregnancy Registry reported zero major malformations among 40 lisdexamfetamine-exposed pregnancies, though this sample is small.²

Clinical benefit: Reduced "crash" effect that contributes to maternal irritability and the transient spikes in sympathomimetic tone that occur with multiple daily doses of IR stimulants.

(3) The Levoamphetamine Factor — Adderall vs. Dexedrine

• Mixed salts (Adderall): The 25% levoamphetamine component provides more peripheral noradrenergic stimulation. Monitor for elevated maternal heart rate and blood pressure more closely than with pure dextroamphetamine.
• Dextroamphetamine (Dexedrine/Zenzedi): Provides more central dopaminergic effect with less peripheral "body load." May be better tolerated in mothers with baseline pregnancy-induced tachycardia or borderline blood pressure.

(4) Dose Titration Across Trimesters

Maternal blood volume increases by approximately 40–50% by the third trimester, and renal clearance of basic amines like amphetamine increases substantially. Some patients require a modest dose increase to maintain the same level of executive function. However, the 2025 continuation data showing increased risks with second/third trimester exposure should be weighed against the functional benefits of continued treatment.³

(5) Duration-of-Exposure Reassessment

Recent evidence supports a structured risk-benefit reassessment at the end of the first trimester:

• First-trimester-only exposure was associated with a higher likelihood of live birth and lower risks of spontaneous abortion and preterm birth.³
• Continued exposure into the second/third trimesters was associated with increased risks of preeclampsia, preterm birth, placental abruption, and SGA.^3,4

This does not mandate discontinuation, but supports an explicit decision point. For patients whose functional impairment may be manageable without medication during lower-demand periods (e.g., early maternity leave), a "drug holiday" may be considered.

(6) Appetite Management

Maternal appetite suppression is a primary mechanism by which stimulants may contribute to lower birth weight and SGA. If the mother is not meeting weight gain targets, options include scheduled medication-free weekends, dose reduction, structured caloric supplementation, or coordination with a perinatal nutritionist.

VIIMonitoring Protocol

VIIIRed Flags & Stop Criteria

Continuation of stimulants is not unconditional. The following warrant urgent re-evaluation, dose reduction, or discontinuation:

• Sustained BP >140/90 mmHg or rise of >30/15 from baseline — halve dose or pause; initiate preeclampsia workup.
• New-onset proteinuria or features of preeclampsia (headache, visual changes, RUQ pain) — stop stimulant; admit/evaluate per obstetric protocol.
• Resting maternal HR >110 bpm despite adequate hydration — reduce dose; rule out hyperthyroidism, anxiety, anemia.
• Failure to gain weight or weight loss in T2/T3 — reduce dose; nutritional consult; rule out hyperemesis or eating disorder.
• SGA on growth ultrasound (EFW <10th percentile) — reduce dose; consider stopping; serial growth scans every 2–3 weeks.
• Abnormal Doppler studies (elevated umbilical artery resistance) — discuss discontinuation with MFM.
• Signs of misuse or escalation — early refill requests, lost prescriptions, sourcing from multiple providers — halt prescribing; refer to addiction medicine.
• New-onset psychosis, mania, or severe anxiety — stop stimulant; psychiatric evaluation.
• Cardiac symptoms — chest pain, palpitations, syncope — stop and cardiac workup.

IXDrug Interactions in Pregnancy

Several interactions become more clinically relevant during pregnancy due to physiologic changes (increased cardiac output, altered protein binding) and the population frequently using these medications.

XSpecial Populations

Adolescent Pregnancy

Adolescents with ADHD have particularly high stakes for medication continuation — educational completion and pregnancy planning behaviors are both medication-responsive. The evidence base does not stratify by age, but clinical practice typically continues stimulants in adolescents using the same monitoring protocol, with added attention to nutrition (adolescent maternal weight gain targets are higher) and social support.

Multiple Gestation

Multiple gestation independently increases preeclampsia risk 2- to 3-fold. The marginal increase from stimulant use is additive on this elevated baseline. Strong consideration should be given to (a) using the lowest effective dose, (b) low-dose aspirin prophylaxis from 12 weeks, and (c) MFM co-management. BP monitoring should be more frequent (weekly from 28 weeks).

IVF and Assisted Reproduction

No direct interaction between stimulants and IVF protocols. However, the stress and time-intensity of IVF cycles may justify continuing stimulants through stimulation and embryo transfer. Once pregnancy is confirmed, the standard pregnancy protocol applies.

Prior Preeclampsia or HELLP

A prior history of preeclampsia is the strongest predictor of recurrence (15–25% recurrence rate). Stimulants are not absolutely contraindicated, but the threshold for continuation should be higher: aspirin prophylaxis is mandatory, BP monitoring should be intensified, and patients should be aware that stimulant discontinuation may be warranted if early preeclamptic features emerge.

Chronic Hypertension

Pre-existing hypertension is a relative contraindication, not absolute. If continuing, ensure BP is optimized on a pregnancy-safe antihypertensive (labetalol, nifedipine, or methyldopa) before stimulant continuation. Avoid co-prescription if BP is not at target.

Pre-Gestational Diabetes

Stimulants can mask hypoglycemic awareness and may slightly elevate fasting glucose. Coordinate with endocrinology; monitor glycemic control more closely (especially in T1 when nausea and appetite changes already disrupt eating patterns).

Substance Use History

A history of stimulant use disorder is a relative contraindication. If a patient with this history requires ADHD treatment, prefer non-stimulant alternatives (atomoxetine, guanfacine ER) or pursue strict prescribing controls (PDMP review, single-prescriber agreement, 30-day fills).

Eating Disorders

Active anorexia nervosa or bulimia is a contraindication. The appetite-suppressing effects of amphetamines can precipitate or worsen restrictive eating, with severe consequences for fetal growth. ADHD-eating disorder comorbidity is common; psychiatric and nutrition support must precede or replace stimulant therapy in pregnancy.

XIDelivery & Anesthesia Considerations

Communication with the Care Team

Notify obstetric anesthesia and pediatrics of stimulant use at the time of labor admission. Document in the prenatal record so it carries to L&D. The information matters for several reasons:

Anesthesia Considerations

• Hemodynamic responsiveness: Chronic amphetamine use can cause down-regulation of adrenergic receptors. Some patients show blunted response to direct-acting vasopressors (phenylephrine, ephedrine) for spinal-induced hypotension. Anesthesia teams may prefer titrated norepinephrine or higher initial doses.
• Avoid ketamine: Co-administration with amphetamines increases sympathetic outflow and risk of intraoperative hypertension. Use alternatives where possible.
• Halogenated agents: Halothane is sensitizing to catecholamines; sevoflurane and desflurane are safer choices if general anesthesia is required.
• Hold morning dose on the day of scheduled cesarean if dose timing allows; for unscheduled labor, dose timing is rarely a clinical concern.

Postpartum Hemorrhage Risk

The Australian dexamphetamine cohort (Russell et al. 2024) is the only study to specifically report postpartum hemorrhage rates, finding that unexposed women had lower odds of PPH than continuers (OR 0.57; 95% CI 0.41–0.80).¹⁷ No other study has directly evaluated this outcome. Standard active management of the third stage of labor is sufficient; no special protocol changes are needed beyond awareness.

Neonatal Care at Delivery

• Pediatric attendance at delivery is not routinely required for therapeutic stimulant exposure but is reasonable for the first 24 hours of observation.
• Watch for: jitteriness, mild irritability, poor feeding, transient tachypnea, sleep disturbance.
• Symptoms typically peak in the first 24–48 hours and resolve within 72 hours.
• No specific treatment is usually required; supportive care (swaddling, low stimulation, frequent small feeds) is sufficient.
• Severe NAS-like syndrome warranting pharmacologic treatment is rare with therapeutic dosing.

Postpartum Resumption

Stimulants can typically be resumed within 24–48 hours postpartum if discontinued for delivery. Postpartum is a high-risk period for ADHD-related functional impairment (sleep deprivation, infant care demands). However, breastfeeding decisions must be addressed separately — this will be covered in the breastfeeding companion course.

XIIAmphetamine vs. Methylphenidate in Pregnancy

The most common clinical question: "If switching between stimulant classes for pregnancy, which is preferred?" Both classes have substantial evidence; the differences are subtle but clinically meaningful.

XIIIClinical Management Pearls

The "Holiday" Strategy

For patients with lower-demand schedules (early maternity leave, remote work, supportive family environment), a stimulant holiday during the first trimester can be discussed though it is not mandatory. The data suggest first-trimester-only exposure carries a favorable risk profile compared with no exposure or continued exposure.³

The Cessation Trap

Australian data show that women who cease stimulants during pregnancy may actually have higher rates of threatened abortion than continuers (OR 2.28; 95% CI 1.00–5.15), possibly reflecting acute symptom relapse, accidents, or stress-related obstetric events.¹⁷ Discontinuation is not a "neutral" or risk-free choice.

Modafinil Caveat

If a patient is using modafinil (off-label for ADHD or for narcolepsy), note that the evidence on modafinil teratogenicity is genuinely conflicting. Regulatory agencies (EMA, Health Canada, FDA) issued warnings based on manufacturer registry data showing major congenital anomaly rates of 13–17%.¹⁹ A Danish registry study (n=49 exposed) found an elevated aOR of 2.7. However, the largest independent multicenter case series (ENTIS, n=150 live births) reported an MCA rate of 2.0% (95% CI 0.6–6.1%), and a Swedish/Norwegian registry analysis found no elevation (crude RR 1.06).¹⁹ Until further data clarify, modafinil should be avoided in pregnancy and patients should be counseled to switch or discontinue prior to conception, but the evidence base for harm is weaker than for other agents commonly labeled "teratogens."

Comorbidity Management

ADHD is highly comorbid with mood, anxiety, and substance use disorders. Treatment decisions should account for the full psychiatric picture — untreated ADHD has been linked to worse mental health outcomes and significant functional impairments during pregnancy.^6,14

Pre-Pregnancy Dose Is Not Pregnancy Dose

Many patients arrive at pregnancy on a dose titrated years earlier. Use the pre-conception visit to verify the dose is still minimally effective — many will tolerate a 25–50% reduction without functional decline, reducing fetal exposure proportionally.

Track Function, Not Just Symptoms

Patient-reported outcomes (driving safety, work performance, missed appointments) are more clinically meaningful than symptom checklists during pregnancy. A brief functional check at each visit ("Have you had any near-misses driving? Missed appointments? Forgotten medications?") flags decompensation early.

XIVFrequently Asked Questions

XVClinic-Ready Tools

The Patient Script

EMR Documentation Template

Visit-by-Visit Checklist